LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $98.14.

A number of equities research analysts have recently weighed in on LMAT shares. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target for the company. Finally, Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Alps Advisors Inc. bought a new position in LeMaitre Vascular in the first quarter worth $354,000. Linden Thomas Advisory Services LLC lifted its holdings in shares of LeMaitre Vascular by 3.2% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 35,591 shares of the medical instruments supplier's stock worth $2,986,000 after acquiring an additional 1,109 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of LeMaitre Vascular by 9.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier's stock valued at $23,921,000 after acquiring an additional 25,680 shares in the last quarter. Principal Financial Group Inc. increased its stake in LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock valued at $9,385,000 after acquiring an additional 3,248 shares during the period. Finally, Consolidated Planning Corp bought a new stake in LeMaitre Vascular in the first quarter valued at about $947,000. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 1.4 %

Shares of LMAT traded down $1.32 during mid-day trading on Friday, hitting $89.43. The stock had a trading volume of 23,890 shares, compared to its average volume of 203,600. LeMaitre Vascular has a fifty-two week low of $65.16 and a fifty-two week high of $109.58. The company has a market cap of $2.02 billion, a PE ratio of 48.87, a PEG ratio of 2.22 and a beta of 0.89. The company's fifty day simple moving average is $86.32 and its two-hundred day simple moving average is $93.43.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. Equities analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.89%. The ex-dividend date was Thursday, March 13th. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.